Christian Herder1,2, Julia M Kannenberg1,2, Corinna Niersmann1,2, Cornelia Huth2,3, Maren Carstensen-Kirberg1,2, Clemens Wittenbecher2,4, Matthias Schulze2,4, Matthias Blüher2,5,6, Wolfgang Rathmann2,7, Annette Peters2,3, Michael Roden1,2,8, Christa Meisinger3, Barbara Thorand2,3. 1. Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany. 2. German Center for Diabetes Research (DZD), München-Neuherberg, Germany. 3. Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. 4. Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany. 5. Department of Medicine, University of Leipzig, Leipzig, Germany. 6. IFB Adiposity Diseases, University of Leipzig, Leipzig, Germany. 7. Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany. 8. Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Abstract
OBJECTIVE: Cross-sectional studies found that higher levels of the novel adipokine omentin-1 were associated with higher adiponectin and lower levels of risk factors for type 2 diabetes, but its relevance for incident type 2 diabetes is currently not understood. Therefore this study investigated whether serum omentin-1 was associated with changes in glycaemia and incident type 2 diabetes independently of adiponectin. DESIGN AND METHODS: The study was based on participants aged 62-81 years from the population-based Cooperative Health Research in the Region of Augsburg (KORA) F4/FF4 cohort. Associations of baseline serum levels of omentin-1 and adiponectin with changes in glycaemia were assessed in 471 non-diabetic participants, and associations between both adipokines and incident type 2 diabetes were assessed in 76 cases and 430 non-cases (follow-up time 6.5 years). Multivariable linear and logistic regression models were adjusted for multiple potential confounders. RESULTS: Higher serum levels of omentin-1 were associated with increases in fasting glucose, 2-h glucose and HbA1c (all P < 0.001) and with incident type 2 diabetes (adjusted odds ratio (OR) (95% CI): 1.40 (1.03; 1.90) per s.d. of log2-transformed omentin-1; P = 0.032). These associations were independent from adiponectin levels, which showed associations with changes in glycaemia and risk of type 2 diabetes in the opposite direction. We found no statistically significant interactions of omentin-1 with adiponectin or sex in the association with incident type 2 diabetes (all P > 0.1). CONCLUSIONS: Systemic levels of omentin-1 were positively associated with increases in glycaemia and incident type 2 diabetes in this older population. These associations were independent of potential confounders including adiponectin.
OBJECTIVE: Cross-sectional studies found that higher levels of the novel adipokine omentin-1 were associated with higher adiponectin and lower levels of risk factors for type 2 diabetes, but its relevance for incident type 2 diabetes is currently not understood. Therefore this study investigated whether serum omentin-1 was associated with changes in glycaemia and incident type 2 diabetes independently of adiponectin. DESIGN AND METHODS: The study was based on participants aged 62-81 years from the population-based Cooperative Health Research in the Region of Augsburg (KORA) F4/FF4 cohort. Associations of baseline serum levels of omentin-1 and adiponectin with changes in glycaemia were assessed in 471 non-diabeticparticipants, and associations between both adipokines and incident type 2 diabetes were assessed in 76 cases and 430 non-cases (follow-up time 6.5 years). Multivariable linear and logistic regression models were adjusted for multiple potential confounders. RESULTS: Higher serum levels of omentin-1 were associated with increases in fasting glucose, 2-hglucose and HbA1c (all P < 0.001) and with incident type 2 diabetes (adjusted odds ratio (OR) (95% CI): 1.40 (1.03; 1.90) per s.d. of log2-transformed omentin-1; P = 0.032). These associations were independent from adiponectin levels, which showed associations with changes in glycaemia and risk of type 2 diabetes in the opposite direction. We found no statistically significant interactions of omentin-1 with adiponectin or sex in the association with incident type 2 diabetes (all P > 0.1). CONCLUSIONS: Systemic levels of omentin-1 were positively associated with increases in glycaemia and incident type 2 diabetes in this older population. These associations were independent of potential confounders including adiponectin.
Authors: Alessandro P Delitala; Maristella Steri; Edoardo Fiorillo; Michele Marongiu; Edward G Lakatta; David Schlessinger; Francesco Cucca Journal: Cytokine Date: 2018-08-30 Impact factor: 3.861
Authors: Barbara Thorand; Martin Reincke; Cornelia Then; Katrin Ritzel; Christian Herder; Holger Then; Chaterina Sujana; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Michael Roden; Haifa Maalmi; Michael Stumvoll; Thomas Meitinger; Martin Bidlingmaier; Jochen Seissler Journal: BMJ Open Diabetes Res Care Date: 2022-01
Authors: Christina Gar; Barbara Thorand; Christian Herder; Chaterina Sujana; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Michael Roden; Michael Stumvoll; Haifa Maalmi; Thomas Meitinger; Holger Then; Jochen Seissler; Cornelia Then Journal: PLoS One Date: 2022-01-06 Impact factor: 3.240
Authors: Dan Ziegler; Barbara Thorand; Haifa Maalmi; Christian Herder; Cornelia Huth; Wolfgang Rathmann; Gidon J Bönhof; Margit Heier; Wolfgang Koenig; Michael Roden; Annette Peters Journal: Int J Obes (Lond) Date: 2022-04-26 Impact factor: 5.551